p53 Immunohistochemistry Defines a Subset of Human Papillomavirus-Independent Penile Squamous Cell Carcinomas With Adverse Prognosis.
Journal
The American journal of surgical pathology
ISSN: 1532-0979
Titre abrégé: Am J Surg Pathol
Pays: United States
ID NLM: 7707904
Informations de publication
Date de publication:
23 Jul 2024
23 Jul 2024
Historique:
medline:
23
7
2024
pubmed:
23
7
2024
entrez:
23
7
2024
Statut:
aheadofprint
Résumé
Penile squamous cell carcinoma (PSCC) is classified into 2 prognostically distinct types: human papillomavirus (HPV)-associated and HPV-independent. However, the impact of p53 status on prognosis remains controversial. We correlated HPV and p53 status with the prognosis of a large series of patients with PSCC. p53 was analyzed according to a recently described immunohistochemical (IHC) pattern-based framework that includes 2 normal and 4 abnormal patterns and closely correlates with TP53 mutational status. A total of 122 patients with surgically treated PSCC in 3 hospitals were included. Based on HPV in situ hybridization and p16 and p53 IHC, the tumors were classified into 3 subtypes: HPV-associated, HPV-independent/p53 normal, and HPV-independent/p53 abnormal. All patients were followed up for at least 22 months (median: 56.9 months). Thirty-six tumors (29%) were HPV-associated, 35 (29%) were HPV-independent/p53 normal, and 51 (42%) were HPV-independent/p53 abnormal. Disease-related deaths were observed in 3/36 (8%), 0/35 (0%) and 14/51 (27%) of the patients, respectively (P< 0.001). A total of 7/14 deaths in the latter group were patients with tumors showing p53 abnormal patterns not recognized in the classic p53 IHC interpretation (basal, null, and cytoplasmic). According to our multivariate analysis, HPV-independent/p53 abnormal tumors and advanced stage were associated with impaired disease-specific survival (hazard ratio = 23.4, 95% CI = 2.7-3095.3; P= 0.001 and 16.3, 95% CI = 1.8-2151.5; P= 0.008, respectively). In conclusion, compared with patients with HPV-associated and HPV-independent/p53-normal PSCC, patients with HPV-independent/p53 abnormal PSCC have worse clinical outcomes. p53 IHC results define 2 prognostic categories in HPV-independent PSCC: HPV-independent/p53-normal tumors as low-risk tumors, whereas HPV-independent/p53-abnormal tumors as aggressive neoplasms.
Identifiants
pubmed: 39040011
doi: 10.1097/PAS.0000000000002291
pii: 00000478-990000000-00398
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
Copyright © 2024 The Author(s). Published by Wolters Kluwer Health, Inc.
Déclaration de conflit d'intérêts
Conflicts of Interest and Source of Funding: The authors have disclosed that they have no significant relationships with, or financial interest in, any commercial companies pertaining to this article.
Références
Parza K, Mustasam A, Ionescu F, et al. The prognostic role of human papillomavirus and p16 status in penile squamous cell carcinoma—a systematic review. Cancers (Basel). 2023;15:3713.
Ribera-Cortada I, Guerrero-Pineda J, Trias I, et al. Pathogenesis of penile squamous cell carcinoma: molecular update and systematic review. Int J Mol Sci. 2022;23:251.
Borque-Fernando Á, Gaya JM, Esteban-Escaño LM, et al. Epidemiology, diagnosis, and management of penile cancer: results from the Spanish national registry of penile cancer. Cancers (Basel). 2023;15:1–12.
Douglawi A, Masterson TA. Penile cancer epidemiology and risk factors: a contemporary review. Curr Opin Urol. 2019;29:145–149.
Menon S, Moch H, Berney DM, et al. WHO 2022 classification of penile and scrotal cancers: updates and evolution. Histopathology. 2023;82:508–520.
Ermakov MS, Kashofer K, Regauer S. Different mutational landscapes in human papillomavirus–induced and human papillomavirus–independent invasive penile squamous cell cancers. Mod Pathol. 2023;36:100250.
Chaux A, Velazquez E, Algaba F, et al. Developments in the pathology of penile squamous cell carcinomas. Urology. 2010;76:S7–S14.
Nazha B, Zhuang T, Wu S, et al. Comprehensive genomic profiling of penile squamous cell carcinoma and the impact of human papillomavirus status on immune-checkpoint inhibitor-related biomarkers. Cancer. 2023;129:3884–3893.
Kashofer K, Winter E, Halbwedl I, et al. HPV-negative penile squamous cell carcinoma: disruptive mutations in the TP53 gene are common. Mod Pathol. 2017;30:1013–1020.
Feber A, Worth DC, Chakravarthy A, et al. CSN1 somatic mutations in penile squamous cell carcinoma. Cancer Res. 2016;76:4720–4727.
Wang Y, Wang K, Chen Y, et al. Mutational landscape of penile squamous cell carcinoma in a Chinese population. Int J Cancer. 2019;145:1280–1289.
Jacob J, Ferry E, Gay L, et al. Comparative genomic profiling of refractory and metastatic penile and nonpenile cutaneous squamous cell carcinoma: implications for selection of systemic therapy. J Urol. 2019;201:541–548.
Lopes A, Bezerra AL, Pinto CA, et al. p53 as a new prognostic factor for lymph node metastasis in penile carcinoma: analysis of 82 patients treated with amputation and bilateral lymphadenectomy. J Urol. 2002;168:81–86.
Teixeira Júnior AAL, da Costa Melo SP, Pinho JD, et al. A comprehensive analysis of penile cancer in the region with the highest worldwide incidence reveals new insights into the disease. BMC Cancer. 2022;22:1–22.
Bellizzi AM. p53 as exemplar next-generation immunohistochemical marker: a molecularly informed, pattern-based approach, methodological considerations, and pan-cancer diagnostic applications. Appl Immunohistochem Mol Morphol AIMM. 2023;31:507–530.
Trias I, Saco A, Marimon L, et al. P53 in penile squamous cell carcinoma: a pattern-based immunohistochemical framework with molecular correlation. Cancers (Basel). 2023;15:2719.
Tessier-Cloutier B, Kortekaas KE, Thompson E, et al. Major p53 immunohistochemical patterns in in situ and invasive squamous cell carcinomas of the vulva and correlation with TP53 mutation status. Mod Pathol. 2020;33:1595–1605.
Liu JY, Li YH, Zhang ZL, et al. The risk factors for the presence of pelvic lymph node metastasis in penile squamous cell carcinoma patients with inguinal lymph node dissection. World J Urol. 2013;31:1519–1524.
Zargar-Shoshtari K, Spiess PE, Berglund AE, et al. Clinical significance of p53 and p16ink4a status in a contemporary North American penile carcinoma cohort. Clin Genitourin Cancer. 2016;14:346–351.
Darragh TM, Colgan TJ, Thomas Cox J, et al. The lower anogenital squamous terminology standardization project for HPV-associated lesions: background and consensus recommendations from the College of American Pathologists and the American Society for Colposcopy and Cervical Pathology. Int J Gynecol Pathol. 2013;32:76–115.
Kidd LC, Chaing S, Chipollini J, et al. Relationship between human papillomavirus and penile cancer-implications for prevention and treatment. Transl Androl Urol. 2017;6:791–802.
McDaniel AS, Hovelson DH, Cani AK, et al. Genomic profiling of penile squamous cell carcinoma reveals new opportunities for targeted therapy. Cancer Res. 2015;75:5219–5227.
Ferrandiz-Pulido C, Masferrer E, Toll A, et al. mTOR signaling pathway in penile squamous cell carcinoma: pmTOR and peIF4E overexpression correlate with aggressive tumor behavior. J Urol. 2013;190:2288–2295.
Zhou X, Wang X. Radioimmunotherapy in HPV-associated head and neck squamous cell carcinoma. Biomedicines. 2022;10:1990.
Szymonowicz KA, Chen J. Biological and clinical aspects of HPV-related cancers. Cancer Biol Med. 2020;17:864–878.
Visser O, Adolfsson J, Rossi S, et al. Incidence and survival of rare urogenital cancers in Europe. Eur J Cancer. 2012;48:456–464.
Mohanty SK, Mishra SK, Bhardwaj N, et al. p53 and p16ink4a as predictive and prognostic biomarkers for nodal metastasis and survival in a contemporary cohort of penile squamous cell carcinoma. Clin Genitourin Cancer. 2021;19:510–520.
Nooij LS, Ter Haar NT, Ruano D, et al. Genomic characterization of vulvar (pre)cancers identifies distinct molecular subtypes with prognostic significance. Clin Cancer Res. 2017;23:6781–6789.
Kortekaas KE, Bastiaannet E, van Doorn HC, et al. Vulvar cancer subclassification by HPV and p53 status results in three clinically distinct subtypes. Gynecol Oncol. 2020;159:649–656.
Carreras-Dieguez N, Saco A, del Pino M, et al. Human papillomavirus and p53 status define three types of vulvar squamous cell carcinomas with distinct clinical, pathological, and prognostic features. Histopathology. 2023;83:17–30.
Bowie J, Singh S, O’hanlon C, et al. A systematic review of non-HPV prognostic biomarkers used in penile squamous cell carcinoma. Turkish J Urol. 2021;47:358–365.
Yanagawa N, Osakabe M, Hayashi M, et al. Detection of HPV-DNA, p53 alterations, and methylation in penile squamous cell carcinoma in Japanese men. Pathol Int. 2008;58:477–482.
Westra WH, Taube JM, Poeta ML, et al. Inverse relationship between human papillomavirus-16 infection and disruptive p53 gene mutations in squamous cell carcinoma of the head and neck. Clin Cancer Res. 2008;14:366–369.
Zięba S, Kowalik A, Zalewski K, et al. Somatic mutation profiling of vulvar cancer: Exploring therapeutic targets. Gynecol Oncol. 2018;150:552–561.
Slaton JW, Morgenstern N, Levy DA, et al. Tumor stage, vascular invasion and the percentage of poorly differentiated cancer: independent prognosticators for inguinal lymph node metastasis in penile squamous cancer. J Urol. 2001;165:1138–1142.